ArticleInternational journal of women's health2025
Correlation Between Serum and Urine β-hCG in Gestational Trophoblastic Neoplasia: A Step Toward Non-Invasive Disease Monitoring.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Gestational Trophoblastic Neoplasia (GTN) are malignant trophoblastic proliferations requiring accurate monitoring to guide treatment and assess disease progression. Serum β-hCG is the standard biomarker for GTN monitoring, but it requires blood collection, which can be invasive and resource-intensive. Urinary β-hCG testing offers a non-invasive alternative, but its clinical reliability in GTN patients remains unclear. This study evaluates the correlation between urinary and serum β-hCG levels in GTN patients, aiming to determine the feasibility of urine β-hCG as a reliable non-invasive monitoring tool. Patients and Methods: A cross-sectional study was conducted at Dr. Hasan Sadikin General Hospital, Bandung, from June 2024 to February 2025, involving 31 patients diagnosed with GTN. A total of 86 paired serum and urine β-hCG samples were analyzed using enzyme-linked immunosorbent assay (ELISA). Data normality was assessed using the Kolmogorov-Smirnov test. Pearson's correlation and simple linear regression were used to evaluate the relationship between serum and urine β-hCG levels. Results: Serum β-hCG levels were significantly higher than urine levels (P < 0.001), but a strong positive correlation was observed between the two (r = 0.985, P < 0.001), with a coefficient of determination Conclusion: Urinary β-hCG exhibits a strong correlation with serum β-hCG in GTN patients, supporting its potential as a non-invasive monitoring tool. However, hydration status, renal function, and possible assay interferences should be considered. Combining serum and urine β-hCG measurements remains the optimal approach for accurate disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.